Facts, not fear: Inside Mexico's pioneering drug harm reduction programs
The initiative, known as 'Checa tu Sustancia' (Check Your Substance), is one of several recent efforts by Mexican civil society to reduce risk among people taking drugs. Spearheaded by the Instituto RIA, a Mexico-based drug policy research and advocacy organization, it aims to address drug use from a public health and social justice perspective, rather than a security one.
In a well-lit corner of the festival, members of the Instituto RIA used reagents and laboratory porcelain plates to test substances that some of the partygoers planned to use and recorded the data. Their analysis uses color changes to indicate what's in the drug: It can reveal the presence of adulterants but not their exact proportion.
They also offered test strips that can detect the presence of fentanyl and nasal sprays of naloxone, a medication designed to rapidly reverse opioid overdose.
Also available were informational flyers detailing the effects of various psychoactive substances and what to do to reduce the risks associated with using them, including simple but critical measures like staying hydrated and eating well.
While some partygoers seemed wary of the initiative, others approached it with curiosity.
'(There is) amazement, but also a little bit of fear, because there is a whole context of criminalization,' said social psychology student Jessica Reyes Moreno, 27, a volunteer with Checa tu Sustancia.
When unexpected substances are detected, users receive detailed information on what they are, about their risks, potential interactions with other substances and dosage adjustments, empowering them to make informed choices.
Harm reduction vs. abstinence
When people understand that the focus is not on prohibiting but on offering information and safe, non-judgmental spaces where they can be heard, trust is built, said Reyes Moreno.
"I think it's information we should have. Because (drug use) is taboo, and if we're uninformed, we can overdose,' said a 34-year-old Mexican partygoer, who requested anonymity due to his use of illicit substances.
He said he feels there isn't enough information about illegal drugs in Mexico, and when there is, it's either confusing or all stigma. "It's just 'Don't do it,' but there's no such thing as 'If you do it, take this precaution.''
The 'don't do it' approach sees abstinence as the solution. In contrast, harm reduction, as defined by Harm Reduction International, aims to minimize the negative health, social and legal effects of substance use by working with people without judgment or requiring them to stop using drugs.
The approach focuses more on people — and their communities— than on the substance.
'We never say, 'you shouldn't consume this,'' said Zara Snapp, a political scientist and director of the Instituto RIA. 'The best way to reduce your risks is not to consume at all. But if you have made the decision to consume, we want you to have as much information as possible so you can take care of yourself.'
'Choose to be happy'
The prohibitionist, hardline approach of the war on drugs in Mexico has led to the perception of the user as someone who is necessarily associated with drug trafficking or criminal activities.
Earlier this year, Mexico President Claudia Sheinbaum unveiled her government's latest anti-drug campaign, 'Stay away from drugs. Fentanyl kills,' which centers on the synthetic opioid responsible in its deadliest year for more than 70,000 overdose deaths each year in the U.S. — now down to an estimated 52,000 deaths a year.
Aimed at young Mexicans, the campaign frames drug use as a public health issue, but some of the videos and glowing neon billboards show scenarios in which death and loneliness (drug use) are contrasted with life and family (not using drugs). They read, 'Choose to be happy.'
'It's not that if I use drugs I won't be happy, or if I stop using drugs I'll be happy,' said Lilia Pacheco, operational director of PrevenCasa A.C., a Tijuana-based organization that runs harm-reduction initiatives for opioid users, mostly deportees from the United States who report that they started using in that country.
'How can we say that to someone who is using because they are cold, hungry or in withdrawal?' she said.
Mexico's health department did not immediately respond to inquiries regarding concerns that its latest campaign stigmatizes drug use.
Dr. Carlos Magis, a professor at Mexico's National Autonomous University's medical school and member of a working group on opioids, said that stigma poses serious challenges. He cited examples of health workers refusing treatment without abstinence, limited access to naloxone or the scarcity of public methadone clinics.
Breaking down fear and social isolation
A recent report by the Mexican Observatory of Mental Health and Drug Use, found that between 2013 and 2024, 5,901 people in Mexico were treated for emergencies related to opioid use, with it trending up.
PrevenCasa reduces harm not by asking users to stop using, but by showing that their lives matter by providing them with safe injection equipment, showers, toiletries and social events like Friday movie nights.
'These interventions improve quality of life, unlike a sign that says 'fentanyl kills you,'" said Pacheco. 'The right to health should be universal.'
Both Pacheco and Snapp emphasized that collective care is at the heart of harm reduction efforts. Whether practiced in the facilities of organizations working on the border or at electronic music festivals, the goal is to break down social isolation and fear in concrete ways.
'This is a service that will save lives...it's very forward-thinking,' said a 43-year-old man, who requested anonymity because he is a user of illicit substances, after members of Instituto RIA tested his ecstasy at a recent festival.
He said that drug testing kits are available in the United States, where he's from, but that in his experience so far, it's something people mostly do on their own or behind closed doors.
The visibility and organization of Checa tu Sustancia was a surprise to him.
'I feel good that I'm not doing anything wrong. I'm just here to have fun, but now with peace of mind,' he said with a smile. He then rejoined his friends and disappeared into the dancing crowd.
____
Follow AP's coverage of Latin America and the Caribbean at https://apnews.com/hub/latin-america
Caterina Morbiato, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
17 minutes ago
- New York Post
Canadian wildfires spark NY air-quality alert: ‘Can pose serious health risks'
Canadian wildfires may be posing 'serious health risks'' to people in New York — prompting an air-quality alert for the state through Monday and a warning for some regions into Tuesday. The metro area's current ailing air quality and hazy skies are hampering the five boroughs, Long Island, Hudson Valley, Adirondacks, eastern Lake Ontario and Central and Western New York regions, according to an alert issued Monday by Gov. Kathy Hochul. Canadian wildfires cloak Manhattan in haze last month. Luiz C. Ribeiro for New York Post Advertisement Pollution from fine particulate matter fueled by the wildfires is expected to push the local Air Quality Index past 100, meaning it will be unhealthy for sensitive groups, including children, older adults and people with heart or lung conditions. In some areas, the index could go above 150 momentarily. The tiny particles can cause eye, nose, and throat irritation along with coughing, sneezing and shortness of breath. They can also worsen asthma and heart disease. Advertisement 'New York continues to track air quality conditions across the state, and people in certain areas may notice visible smoke throughout the day,' Hochul said in a statement. The advisory remains in effect through 11:59 p.m. Monday, but weather patterns are anticipated to bring more spikes in smoke in certain regions across the state Tuesday. Wildfires destroy scores of acres in British Columbia. AP Officials urged everyone in sensitive groups to check their local Air Quality Index and take precautions, including limiting outdoor activity. Advertisement 'Poor air quality can pose serious health risks — especially for those with heart conditions, lung diseases, such as asthma, young children, those over 65 years old, and pregnant individuals,' New York Health Commissioner Dr. James McDonald said in a statement. 'To reduce exposure, limit strenuous activity outdoors.' The smoky situation is just the latest to cloud city skies this year. Multiple alerts were issued in June when ozone pollution and wildfire haze from Canada triggered warnings across the tri-state area. Advertisement More than 700 active wildfires are currently blazing across Canada, with roughly two-thirds of them still out of control, according to the Canadian Interagency Forest Fire Center.

Miami Herald
an hour ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
Yahoo
2 hours ago
- Yahoo
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America. Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. Knight and Incyte had entered into an exclusive supply and distribution agreement for MINVUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) in Latin America in September 2021. Retifanlimab is approved in the United States and Europe for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1 Based on epidemiological data from two Brazilian registries, there are an estimated 550 – 1,250 new cases of MCC each year across Brazil, Mexico, Colombia and Argentina.2 Retifanlimab is also approved by the U.S. Food and Drug Administration (FDA) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).1 In addition, the FDA approved retifanlimab as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.1 While epidemiological data for SCAC in LATAM is limited, there are approximately 2,700 – 4,000 new cases of SCAC each year in Brazil, Mexico, Colombia and Argentina.3 Axatilimab received FDA approval in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.4 Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor's immune cells attack the recipient's tissues, potentially affecting multiple organs such as the skin, liver, lungs, and gastrointestinal tract. There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.5 'We are thrilled to expand our partnership with Incyte and for the opportunity to bring two innovative biologic products to the LATAM region,' said Samira Sakhia, President and CEO of Knight Therapeutics. 'These therapies are highly complementary to our existing portfolio and will significantly strengthen our presence in oncology and hematology, reinforcing our commitment to delivering transformative treatments to patients across Latin America.' 'As a partner, Knight, has an extensive track record of successful collaborations as well as strong distribution capabilities in Latin America,' said Lee Heeson, Executive Vice President and Head of Incyte International. 'We look forward to continuing to work together and to expanding our existing partnership for tafasitamab and pemigatinib to include retifanlimab and axatilimab so that eligible patients in the region can access our innovative medicines.' About Retifanlimab ZYNYZ® (retifanlimab-dlwr) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S.1 ZYNYZ® is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1 ZYNYZ® is marketed by Incyte in the United States. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. ZYNYZ® is a registered trademark of Incyte. About Axatilimab NIKTIMVO™ (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg .4 In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in cGVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD; a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids which are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). NIKTIMVO™ is a trademark of Incyte. All other trademarks are the property of their respective owners. References Incyte Corporation. ZYNYZ (retifanlimab-dlwr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from Melo, Andreia C de, and Luiz C Santos Thuler. 'Trends in the Incidence and Morbidity of Merkel Cell Carcinoma in Brazil.' Future Oncology 17, no. 22 (May 7, 2021): 2857–65. Mignozzi, Silvia, Claudia Santucci, Matteo Malvezzi, Fabio Levi, Carlo La Vecchia, and Eva Negri. 'Global Trends in Anal Cancer Incidence and Mortality.' European Journal of Cancer Prevention 33, no. 2 (November 27, 2023): 77–86. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from Associação Brasileira De Transplante De Órgãos. 'Registro Brasileiro de Transplantes.'XXV No. 3. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: